Chronic allograft nephropathy

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 2, 2008, Pages 149-155

  Najafian, Behzad ^a   Kasiske, Bertram L ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

C4d; Calcineurin inhibitor toxicity; Chronic rejection; Transplant glomerulopathy

Indexed keywords

CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CORTICOSTEROID; CYCLOSPORIN A; HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

CHRONIC ALLOGRAFT NEPHROPATHY; DISEASE COURSE; DRUG BLOOD LEVEL; GLOMERULUS FILTRATION; GRAFT SURVIVAL; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PATHOGENESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RENAL GRAFT DYSFUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ACUTE DISEASE; ANIMALS; AUTOANTIBODIES; CALCINEURIN; CHRONIC DISEASE; GLOMERULAR BASEMENT MEMBRANE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 39149135506     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f4e514     Document Type: Review

References (76)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725-1730.
2. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346:580-590.
3. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342:605-612.
4. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic stratgies? Am J Transplant 2004; 4:1289-1295.
5. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57:307-313.
6. Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002; 62:704-714.
7. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10:167-181.
8. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66:1736-1740.
9. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56:783-793.
10. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333.
11. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518-526.
12. Dean DE, Kamath S, Peddi VR, et al. A blinded retrospective analysis of renal allograft pathology using the Banff schema: implications for clinical management. Transplantation 1999; 68:642-645.
13. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411-422.
14. Solez K. International standardization of criteria for histologic diagnosis of chronic rejection in renal allografts. Clin Transplant 1994; 8:345-350.
15. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713-723.
16. Cornell LD, Colvin RB. Chronic allograft nephropathy. Curr Opin Nephrol Hypertens 2005; 14:229-234.
17. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033-1041.
18. Davenport A, Younie ME, Parsons JE, Klouda PT. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant 1994; 9:1315-1319.
19. Worthington JE, Martin S, Al Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75:1034-1040.
20. Mihatsch MJ, Ryffel B, Gudat F. Morphological criteria of chronic rejection: differential diagnosis, including cyclosporine nephropathy. Transplant Proc 1993; 25:2031-2037.
21. Paul LC, Hayry P, Foegh M, et al. Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: joint proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. Transplant Proc 1993; 25:2022-2023.
22. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5:807-817.
23. Sis B, Kaplan B, Halloran PF. Histologic findings from positive crossmatch or ABO-incompatible renal allografts: accomodation or chronic allograft injury? Am J Transplant 2006; 6:1753-1754.
24. Monga G, Mazzucco G, Messina M, et al. Intertubular capillary changes in kidney allografts: a morphologic investigation on 61 renal specimens. Mod Pathol 1992; 5:125-130.
25. Ivanyi B, Fahmy H, Brown H, et al. Peritubular capillaries in chronic renal allograft rejection: a quantitative ultrastructural study. Hum Pathol 2000; 31:1129-1138.
26. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12:574-582.
27. Sijpkens YW, Joosten SA, Wong MC, et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65:2409-2418.
28. Zollinger HU, Moppert J, Thiel G, Rohr HP. Morphology and pathogenesis of glomerulopathy in cadaver kidney allografts treated with antilymphocyte globulin. Curr Top Pathol 1973; 57:1-48.
29. Ivanyi B. Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection. Nephrol Dial Transplant 2003; 18:655-660.
30. Akalin E, Dikman S, Murphy B, et al. Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 2003; 3:1116-1120.
31. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7:2124-2132. In this study, the cumulative 5-year incidence of transplant glomerulopathy, diagnosed by either protocol or clinical biopsies, was 20%.
32. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13:2371-2380.
33. Al Aly Z, Yalamanchili P, Cortese C, et al. C4d peritubular capillary staining in chronic allograft nephropathy and transplant glomerulopathy: an uncommon finding. Transpl Int 2005; 18:800-805.
34. Nickeleit V, Zeiler M, Gudat F, et al. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13:242-251.
35. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6:1841-1847. In the setting of ABO-incompatible transplantation, transplant glomerulopathy, even when subclinical, conveys a poor prognosis, with approximately 50% of grafts failing by 3 years after diagnosis. These data suggest that antibody-mediated rejection may play an important role in the pathogenesis of transplant glomerulopathy.
36. Deber RB, Blidner IN, Carr LM, Barnsley JM. The impact of selected patient characteristics on practitioners' treatment recommendations for end-stage renal disease. Med Care 1985; 23:95-109.
37. Drachenberg CB, Steinberger E, Hoehn-Saric E, et al. Specificity of intertubular capillary changes: comparative ultrastructural studies in renal allografts and native kidneys. Ultrastruct Pathol 1997; 21:227-233.
38. Ivanyi B, Kemeny E, Szederkenyi E, et al. The value of electron microscopy in the diagnosis of chronic renal allograft rejection. Mod Pathol 2001; 14:1200-1208.
39. Aita K, Yamaguchi Y, Horita S, et al. Thickening of the peritubular capillary basement membrane is a useful diagnostic marker of chronic rejection in renal allografts. Am J Transplant 2007; 7:923-929. Although cross-sectional, this study suggests that in addition to peritubular capillary basement membrane layering on electron microscopy, thickening of peritubular capillary basement membranes on light microscopy is associated with CAN. If confirmed, this could have practical implications for the interpretation of biopsies with light microscopy.
40. Lerut E, Naesens M, Kuypers DR, et al. Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation 2007; 83:1416-1422. Subclinical peritubular capillary inflammation in protocol biopsies 3 months after transplantation was invariably associated with late peritubular capillary basement membrane layering. If confirmed, this could have important implications for our understanding of the pathogenesis of peritubular capillary basement membrane layering and CAN.
41. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7:1743-1752. Of those patients with transplant glomerulopathy 70% had anti-HLA antibodies, and 85% of these were donor-specific. Class II, or class I and class II, were more common than class I alone. These data suggest that donor-specific, anti-HLA antibodies could play a major role in the pathogenesis of transplant glomerulopathy.
42. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7:864-871. In serial determinations, anti-HLA antibodies were strongly associated with subsequent graft failure.
43. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7:408-415.
44. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7:576-585. Of 83 patients receiving HLA-incompatible kidney allografts, 10 developed subclinical, antibody-mediated rejection and had a greater increase in CAN scores on follow-up biopsies, compared with 24 patients without subclinical antibody-mediated rejection.
45. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55:752-757.
46. Massy ZA, Guijarro C, Wiederkehr MR, et al. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49:518-524.
47. Kasiske BL, Kalil RSN, Lee HS, Rao KV. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int 1991; 40:514-524.
48. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57:857-859.
49. Nankivell BJ, Fenton-Lee CA, Kuypers DR, et al. Effect of histological damage on long-termkidney transplant outcome. Transplantation 2001; 71:515-523.
50. Schweitzer EJ, Drachenberg CB, Anderson L, et al. Significance of the Banff borderline biopsy. Am J Kidney Dis 1996; 28:585-588.
51. Nankivell BJ, Borrows RJ, Fung CL, et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78:242-249.
52. McDonald S, Russ G, Campbell S, Chadban S. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant 2007; 7:1201-1208. This registry study confirms that acute rejection is associated with late allograft failure, but that a reduction in the incidence of acute rejection has not led to a reduction in the incidence of late allograft failure.
53. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78:557-565.
54. Cosio FG, Amer H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation 2007; 83:411-416.
55. Naesens M, Lerut E, Damme BV, et al. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007; 7:2114-2123. The results of this protocol biopsy study found that, during the first year after transplantation, low levels of the CNI tacrolimus were associated with CAN whereas higher tacrolimus levels did not correlate with lesions of CNI toxicity. Thus, these data suggest that during the first year after transplantation acute rejection from low tacrolimus levels may be more important than potentially toxic high tacrolimus levels in causing CAN.
56. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82:1153-1162. This meta-analysis suggests that converting patients with chronic allograft dysfunction from CNIs to sirolimus improves short-term function, but that follow up in these studies is insufficient to determine the effect on graft survival.
57. Merkel S, Mogilevskaja N, Mengel M, et al. Side effects of sirolimus. Transplant Proc 2006; 38:714-715.
58. Pinheiro HS, Amaro TA, Braga AM, Bastos MG. Postrapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center. Transplant Proc 2006; 38:3476-3478.
59. Joss N, Rodger RS, McMillan MA, Junor BJ. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation: 15-year outcome data. Transplantation 2007; 83:582-587.
60. Nickerson P, Jeffery J, Gough J, et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998; 9:482-487.
61. Terasaki PI, Koyama H, Cecka JM, Gjertson DW. The hyperfiltration hypothesis in human renal transplantation. Transplantation 1994; 57:1450-1454.
62. Humar A, Johnson EM, Payne WD, et al. Effect of initial slow graft function on renal allograft rejection and survival. Clin Transplant 1997; 11:623-627.
63. Weight SC, Bell PR, Nicholson ML. Renal ischaemia-reperfusion injury. Br J Surg 1996; 83:162-170.
64. Yilmaz S, McLaughlin K, Paavonen T, et al. Clinical predictors of renal allograft histopathology: a comparative study of single-lesion histology versus a composite, quantitative scoring system. Transplantation 2007; 83:671-676.
65. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int 1995; 48 (Suppl 52):S56-S59.
66. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53:217-222.
67. Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7:2350-2360.
68. Tylicki L, Biedunkiewicz B, Chamienia A, et al. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 2007; 7:243-248.
69. Rademacher J, Mengel M, Ellis S, et al. The renal arterial resistance index and renal allograft survival. N Engl J Med 2003; 349:115-124.
70. Schwenger V, Keller T, Hofmann N, et al. Color Doppler indices of renal allografts depend on vascular stiffness of the transplant recipients. Am J Transplant 2006; 6:2721-2724.
71. Halimi JM, Buchler M, Al Najjar A, et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and nonproteinuric renal transplant recipients. Am J Transplant 2007; 7:618-625. Both microalbuminuria and macroalbuminuria were strong risk factors for death-censored graft failure in this study. Among 219 without proteinuria, microalbuminuria also predicted death-censored graft failure.
72. Schaub S, Mayr M, Honger G, et al. Detection of subclinical tubular injury after renal transplantation: comparison of urine protein analysis with allograft histopathology. Transplantation 2007; 84:104-112.
73. Hotchkiss H, Chu TT, Hancock WW, et al. Differential expression of profi-brotic and growth factors in chronic allograft nephropathy. Transplantation 2006; 81:342-349.
74. Mas V, Maluf D, Archer K, et al. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation 2007; 83:448-457.
75. Mas VR, Maluf DG, Archer KJ, et al. Study of mRNA growth factors in urinary cells of kidney transplant recipients as predictors of chronic allograft nephropathy. Transplantation 2005; 80:1686-1691.
76. Eikmans M, Roos-van Groningen MC, Sijpkens YW, et al. Expression of surfactant protein-C, S100A8, S100A9, and B cell markers in renal allografts: investigation of the prognostic value. J Am Soc Nephrol 2005; 16:3771-3786.